Delivery Order SPE2DB22D1103-SPE2DB25FTSE9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $14,615.04 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 18, 2025, with completion scheduled for July 21, 2025. This contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 19, 2025. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small transaction within the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,356.64 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed price delivery order, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside award. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $2,724.55 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $10,202.44 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract covers pharmaceutical supplies to support federal...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTSE9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,015.96 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (semaglutide injection) on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and serves as a critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems, including specialty drugs, vaccines, and medical devices across multiple therapeutic domains. The contract vehicle enables the company to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with flexible pharmaceutical support capabilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/18/25 |